What are the effects of HMPV infection in immunocompromised patients?

Question

Hello doctor,

A 67-year-old immunocompromised patient who has undergone a lung transplant is experiencing severe pneumonia caused by human metapneumovirus (HMPV). This patient is 180 days post-transplant and is currently on a regimen of Tacrolimus and Mycophenolate Mofetil (MMF). The patient requires 3.95 gallons of OptiFlow and has an oxygen saturation level of 88 percent. A CT scan reveals diffuse ground-glass opacities (GGOs) with a crazy paving pattern. The bronchoalveolar lavage (BAL) shows a viral load exceeding 2 million copies. The patient is already receiving broad-spectrum antibiotics. A recent episode of rejection was managed with pulse steroid therapy. The transplant team is contemplating the use of ribavirin and evaluating the potential role of intravenous immunoglobulin (IVIG) while also expressing concerns regarding the reduction of immunosuppression.

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Treatment in such cases includes;

Ribavirin: This antiviral medication has been used to treat HMPV infections, but its effectiveness is debated. It may be considered, but the potential benefits and risks should be weighed.
IVIG (Intravenous Immunoglobulin): IVIG has been used to treat severe viral infections, including HMPV. It may help reduce the viral load and alleviate symptoms.
Immunosuppression: The transplant team is concerned about reducing immunosuppression, as this may increase the risk of rejection. However, the severity of the HMPV infection may necessitate adjusting the immunosuppressive regimen.

Request for Additional Information to provide better guidance, it would be helpful to share the following reports:

1. CBC (complete blood count).

2. ESR (erythrocyte sedimentation rate).

3. CRP (C-reactive protein).

4. RFT (renal function test).

5. PCT (procalcitonin).

6. Blood cultures.

7. ET (endotracheal) culture.

8. CT scan plates.

9. BAL (bronchoalveolar lavage) reports.

10. Ongoing treatment details, including medication dosages and administration schedules.

Please share these reports to facilitate a more informed discussion.

I hope this information helps you.

Thank you.